Fibrotic valvular heart disease subsequent to bromocriptine treatment

Cardiology in Review

Volumn 10, Issue 6, 2002, Pages 334-336

  Serratrice, Jacques ^a   Disdier, Patrick ^a   Habib, Gilbert ^a   Viallet, François ^a   Weiller, Pierre Jean ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

Bromocriptine; Fibrosis; Heart

Indexed keywords

BROMOCRIPTINE; ERGOT ALKALOID; ERGOTAMINE; LEVODOPA;

ADULT; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; HEART MUSCLE FIBROSIS; HUMAN; MALE; PARKINSON DISEASE; VALVULAR HEART DISEASE; VASCULAR DISEASE;

EID: 0036843292     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045415-200211000-00005     Document Type: Article

References (5)

1. Avierinos JF, Habib G, Garcia M, et al. Apport de l'echocardiographie dans le diagnostic des tumeurs carcinoïdes. A propos de 4 observations. Arch Mal Coeur Vaiss 2000;93:277-283.
2. Austin SM, El Hayek A, Comianos M, et al. Mitral valve disease associated with long-term ergotamine use. South Med J 1993;86:1179-1181.
3. Ling LH, Ahlskog JE, Munger TM, et al. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist (cabergoline) for Parkinson's disease. Mayo Clin Proc 1999;74:371-375.
4. Rinne UK. Pleuropulmonary changes during long term Bromocriptine treatment for Parkinson's disease. Lancet 1981; 1:44.
5. Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000;57:75-81.